Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Males and females at least 18 years of age with moderate to severe plaque psoriasis
You may not be if
Forms of psoriasis other than chronic plaque psoriasis
Previous exposure to IL-17A or IL-17 receptor targeting agents.
Other active or ongoing disease that may interfere with evaluation of psoriasis or places the patient at unacceptable risk
Clareo Health | Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
